Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON50873
NL-OMON50873
Completed
Not Applicable

A RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO-CONTROLLED THOROUGH QTC STUDY WITH SINGLE ORAL DOSES OF CEDAZURIDINE IN HEALTHY SUBJECTS - Thorough QT Assessment of Cedazuridine in Healthy Subjects

Astex Pharmaceuticals, Inc0 sites36 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLeukemia10024324

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia
Sponsor
Astex Pharmaceuticals, Inc
Enrollment
36
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Sex : male or female; females of nonchildbearing potential, or
  • •postmenopausal.
  • •2\. Age : 18 to 55 years, inclusive, at screening.
  • •3\. Body mass index (BMI) : 18\.0 to 32\.0 kg/m2, inclusive.
  • •4\. Weight : \>\=50 kg, inclusive.
  • •5\. Status : healthy subjects.

Exclusion Criteria

  • •1\. Employee of PRA or the Sponsor.
  • •2\. History of relevant drug and/or food allergies.
  • •3\. History of alcohol abuse or drug addiction (including soft drugs like
  • •cannabis products).
  • •4\. History or presence of atrioventricular block (any degree) or sick sinus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
A RANDOMIZED, DOUBLED-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FLUTICASONE FUROATE INHALATION POWDER AND FLUTICASONE PROPIONATE INHAATION POWDER IN THE TREATMENT OF ASTHMA IN ADULTS AND ADOLESCENTS NOT CURRENTLY TREATED WITH INHALED CORTICOSTEROIDS
PER-076-11GLAXOSMITHKLINE PERU S.A.,119
Unknown
Not Applicable
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AFTER TWELVE WEEKS OF TREATMENT, COMPARED PLACEBO AND ETANERCEPT AND TO ASSESS THE SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO ONE YEAR IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS
PER-054-11OVARTIS BIOSCIENSES PERU S.A.,
Active, not recruiting
Phase 1
A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TURANDOT) - TURANDOTCrohn’s Disease (CD) and Ulcerative Colitis (UC)MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-002030-37-BEPfizer Inc.357
Active, not recruiting
Not Applicable
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-002789-18-DEMenarini Ricerche S.p.A240
Active, not recruiting
Phase 1
A PHASE II STUDY ASSESSING RANOLAZINE IN ATRIAL FIBRILLATION FOLLOWING AN ELECTRICAL CARDIOVERSIOON-PERMANENT ATRIAL FIBRILLATIONMedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-002789-18-ESMENARINI RICERCHE S.P.A241